Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the collaboration, Guardant Health and AnHeart Therapeutics will develop Guardant360® CDx and Guardant360 TissueNext™ assays as companion diagnostics for AB-106 (taletrectinib) in Advanced or Metastatic ROS1-Positive NSCLC.
Lead Product(s): Taletrectinib
Therapeutic Area: Oncology Product Name: AB-106
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AnHeart Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 02, 2023
Details:
Analysis utilizing GuardantINFORM™ real-world evidence platform shows cumulative incidence of EGFR C797X mutation was 12.5 percent in NSCLC patients likely to progress after first-line Tagrisso (osimertinib) treatment.
Lead Product(s): Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Tagrisso
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Blueprint Medicines
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2022